Location: Palo Alto, CA / Princeton, NJ ONSITE

About Summit

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

• HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

• HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

• HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

• HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Position Summary:

Summit Therapeutics is seeking a Director, Health Economics & Outcomes Research, to join our mission of developing Ivonescimab, a novel and unique immunotherapy with the potential to help patients suffering from life-threatening cancers.

The Director of Health Economics and Outcomes Research (HEOR) will lead initiatives to generate and communicate evidence that enhances product value and informs access strategies. This position entails developing and executing comprehensive health economics, outcomes research, and real-world evidence (RWE) plans in alignment with medical affairs strategies, clinical development objectives, and commercial approaches to support product value propositions and optimize market access. The role is responsible for disseminating scientific evidence to inform providers, payers, population-based decision makers (PBDMs), and patients about the value proposition of ivonescimab.

The ideal candidate will thrive in a fast-paced environment and be adept at collaborating with internal cross-functional teams and external stakeholders.

Roles and responsibilities:

• Lead global and regional HEOR strategies and evidence generation projects to support market access and product value.
• Collaborate with Medical Affairs and Market Access to integrate HEOR initiatives into broader strategies and stakeholder engagement plans.
• Oversee the development, review, and dissemination of high-quality HEOR outputs, including protocols, analytic plans, publications, and field materials.
• Provide training and develop relevant health care economic information (HCEI) materials to support field teams
• Support value demonstration tactics for Health Technology Assessment (HTA), including EU Joint Clinical Assessment (JCA) and payer assessments
• Maintain awareness of the quickly evolving global HTA and reimbursement landscape, help educate organization on developments within HEOR
• Ensure scientific rigor and strategic alignment in all evidence generation activities.
• Lead development of high-quality publications, posters, and presentations to communicate HEOR findings effectively
• Develop and maintain strong alignment with the managed care liaison team to obtain insights from external stakeholders and adjust evidence generation plans accordingly
• All other duties as assigned

Experience/Education:

• Advanced degree (Master’s, PharmD or PhD) in Health Economics, Epidemiology, Outcomes Research, Public Health or related field
• Minimum 8+ years relevant experience in healthcare industry with direct experience in global value proposition development, payer, HTA, and relevant policymaker interactions and strong patient-centered focus
• Direct experience in Oncology, preferably non-small cell lung cancer (NSCLC)
• Expertise in US and global market access, reimbursement processes, and health technology assessment methods.
• Proficiency in cost effectiveness analysis (CEA), budget impact modeling (BIM), systematic literature reviews (SLRs), indirect treatment comparisons (ITCs), statistical analyses, and real-world evidence (RWE) generation.
• Strong analytical capabilities and excellent communication skills, with a track record of peer-reviewed publications
• Ability to work collaboratively across diverse teams and manage multiple stakeholders, and proactively drive goals

The pay range for this role is $203,000-$253,500 annually. Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.

Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.